<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We undertook a phase I-II trial in elderly (age greater than or equal to 60 years) untreated <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) patients using brief, intensive therapy to improve induction rates and overall survival in older <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-one patients ranging in age from 60 to 81 years (median, 66 years) were treated using either a 4- or 5-day course of high-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi>, 3 g/m2 intravenously (IV) every 12 hours; followed by <z:chebi fb="0" ids="41977">daunorubicin</z:chebi>, 45 mg/m2/d IV bolus for 3 consecutive days </plain></SENT>
<SENT sid="2" pm="."><plain>Thirteen patients were entered at the first dose level (a 4-day course or eight doses of <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi>), whereas eight patients underwent therapy at the second dose level (a 5-day course or ten doses) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients who achieved a complete remission received a repeat course of high-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> and <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> within 4 weeks of attaining remission </plain></SENT>
<SENT sid="4" pm="."><plain>Seven patients had an antecedant history of a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infection</z:e> was the major complication experienced by this elderly patient group, and included ten episodes of <z:e sem="disease" ids="C0004610" disease_type="Disease or Syndrome" abbrv="">bacteremia</z:e> or <z:e sem="disease" ids="C0085082" disease_type="Disease or Syndrome" abbrv="">fungemia</z:e> (four of which were fatal) and five cases of <z:hpo ids='HP_0002090'>pneumonia</z:hpo> (one fatality) </plain></SENT>
<SENT sid="6" pm="."><plain>Nine of the 21 patients (three of 13 at the first dose level and six of eight at the second dose level) achieved a complete remission </plain></SENT>
<SENT sid="7" pm="."><plain>Median remission duration was 9 months (range, 4-19+ months) </plain></SENT>
<SENT sid="8" pm="."><plain>Although high-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> plus <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> was an effective antileukemic therapy, it is too toxic to recommend for most elderly leukemic patients </plain></SENT>
</text></document>